Exercise of Options, Director Dealing and TVR

Tissue Regenix Group PLC

18 June 2024

 

Tissue Regenix Group plc

('Tissue Regenix', the 'Group', or the 'Company')

Exercise of Options, Director Dealing and Total Voting Rights

Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company, announces that the Company has issued and allotted 821,167 new ordinary shares of 0.1 pence each ("Ordinary Shares") following the exercise of an aggregate number of 821,167 share options (the "Options") by Daniel Lee (Chief Executive Officer), David Cocke (Chief Financial Officer), Kirsten Lund (PDMR) and other employees, issued under the Company's Long-Term Incentive Plan. Each employee disposed of such number of Ordinary Shares required to cover the associated cost attached to the exercise of Options.

	Numer of Options exercised	Numbers of Ordinary Shares sold	Price of Ordinary Shares sold	Resultant beneficial holding	% of issued share capital
Daniel Lee	283,216	87,611	61 pence	282,512	0.4
David Cocke	146,491	63,207	61 pence	154,489	0.2
Kirsten Lund	109,091	60,751	61 pence	113,557	0.2

Application has been made for the 821,167 new Ordinary Shares to be admitted to trading on AIM. It is expected that dealings in these new Ordinary Shares will commence at 8.00 a.m. on 27 June 2024. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Following Admission, the Company will have in issue a total of 71,395,635 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore, the number of total voting rights for the Company will be 71,395,635.

For more information:

Tissue Regenix Group plc		www.tissueregenix.com
David Cocke, Chief Financial Officer		via Walbrook PR
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR and IR)	Tel: [phone]
Alice Woodings/Charlotte Edgar	[e-mail]

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

Further details of the PDMR dealing are included below. This information has been provided in accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Daniel Lee
2.	Reason for the Notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Tissue Regenix Group plc
b)	LEI	213800PNOD5UHQUFJI36
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 0.1p each
	Identification code	GB00B5SGVL29
b)	Nature of the transaction	Exercise of options and sale of Ordinary Shares
c)	Price(s) and volume(s)	Options exercised: 283,216 Ordinary Shares at an exercise price of 10 pence each Ordinary Shares sold: 87,611 shares at 61 pence each
d)	Aggregated information: ·      Aggregated volume ·      Price	N/A
e)	Date of the transaction	18 June 2024
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	David Cocke
2.	Reason for the Notification
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Tissue Regenix Group plc
b)	LEI	213800PNOD5UHQUFJI36
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 0.1p each
	Identification code	GB00B5SGVL29
b)	Nature of the transaction	Exercise of options and sale of Ordinary Shares
c)	Price(s) and volume(s)	Options exercised: 146,491 Ordinary Shares at an exercise price of 10 pence each Ordinary Shares sold: 63,207 shares at 61 pence each
d)	Aggregated information: ·      Aggregated volume ·      Price	N/A
e)	Date of the transaction	18 June 2024
f)	Place of the transaction	London Stock Exchange, AIM Market

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Kirsten Lund
2.	Reason for the Notification
a)	Position/status	PDMR
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Tissue Regenix Group plc
b)	LEI	213800PNOD5UHQUFJI36
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 0.1p each
	Identification code	GB00B5SGVL29
b)	Nature of the transaction	Exercise of options and sale of Ordinary Shares
c)	Price(s) and volume(s)	Options exercised: 109,091 Ordinary Shares at an exercise price of 10 pence each Ordinary Shares sold: 60,751 shares at 61 pence each
d)	Aggregated information: ·      Aggregated volume ·      Price	N/A
e)	Date of the transaction	18 June 2024
f)	Place of the transaction	London Stock Exchange, AIM Market

 

END